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Oncogenic Ras mutations occur in various leukemias. It was unclear if, besides the direct
transforming effect via constant RAS/MEK/ERK signaling, an inflammation-related effect of
KRAS contributes to the disease. Here, we identify a functional link between oncogenic
KrasG12D and NLRP3 inflammasome activation in murine and human cells. Mice expressing
active KrasG12D in the hematopoietic system developed myeloproliferation and cytopenia,
which is reversed in KrasG12D mice lacking NLRP3 in the hematopoietic system. Therapeutic
IL-1-receptor blockade or NLRP3-inhibition reduces myeloproliferation and improves hema-
topoiesis. Mechanistically, KrasG12D-RAC1 activation induces reactive oxygen species (ROS)
production causing NLRP3 inflammasome-activation. In agreement with our observations in
mice, patient-derived myeloid leukemia cells exhibit KRAS/RAC1/ROS/NLRP3/IL-1β axis
activity. Our findings indicate that oncogenic KRAS not only act via its canonical oncogenic
driver function, but also enhances the activation of the pro-inflammatory RAC1/ROS/NLRP3/
IL-1β axis. This paves the way for a therapeutic approach based on immune modulation via
NLRP3 blockade in KRAS-mutant myeloid malignancies.
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ctivating mutations of NRAS and KRAS genes were
reported to occur in 18–32% of acute myeloid leukemia
(AML)1,2, in 11–38% of chronic myelomonocytic leuke-
mia (CMML)3,4 and in 25–35% of juvenile myelomonocytic
leukemia (JMML) patients5,6. JMML is an aggressive myelopro-
liferative disease (MPD) of early childhood characterized clini-
cally by the overproduction of myelomonocytic cells7. Other
mutations found in this disease include mutations in the tumor
suppressor gene NF18, CBL and mutations in PTPN119, which
also activate the RAS/extracellular-signal-regulated kinase (ERK)
signaling pathway10, reviewed in ref. 11. CMML is a clonal stem
cell disorder associated with peripheral blood monocytosis,
myeloid cell proliferation with myeloid cell dysplasia and inef-
fective hematopoiesis, and can transform to AML12.
Since the RAS/RAF/MEK/ERK cascade couples signals from
cell surface receptors to transcription factors in non-malignant
immune cells13, we hypothesized that in addition to the onco-
genic signal, inflammatory mechanisms may drive the prolifera-
tion of myeloid cells and cause fever, wasting syndrome and
failure to thrive, which is frequently observed in JMML, CMML
and more rarely in AML patients. This hypothesis was also based
on our previous work showing that signaling caused by FLT3-
ITD and JAK2-V617F oncoproteins can affect the expression of
the inflammation-related molecules IL-1514 and PD-L115,
respectively. In support of the concept that RAS/ERK signaling
plays a role in inflammation, recent studies had shown that
ERK1/2 phosphorylation is critical for allogeneic immune acti-
vation during graft-versus-host disease (GVHD)16 and MEK
inhibition blocked these pro-inflammatory events17. A major
inflammatory mediator in GVHD is the NLRP3 inflammasome18
and caspase-1, the effector protease of the NLRP3 inflammasome,
which is essential for pro-IL-1β maturation19.
We found in microarray-based studies that NLRP3 expression
was upregulated in murine hematopoietic bone marrow (BM)
cells harboring active inducible KrasG12D allele. In agreement
with a functional role of NLRP3 in the myeloid compartment,
KrasG12D BM-derived dendritic cells (BMDCs) showed increased
IL-1β production and caspase-1 activation compared to wildtype
(WT) cells. While mice expressing active KrasG12D selectively in
the hematopoietic system developed cytopenia and myeloproli-
feration, these disease features were abrogated in KrasG12D mice
lacking NLRP3 in the hematopoietic system. The findings in the
mouse models could be recapitulated in patient samples of
JMML, CMML, and AML patients carrying activating KRAS
mutations. This study shows that oncogenic KrasG12D leads to
activation of the RAC1/ROS/NLRP3/IL-1β axis, which could be
the basis for therapeutic approaches.
Results
Oncogenic KrasG12D causes NLRP3 inflammasome and
caspase-1 activation. To understand whether oncogenic
KrasG12D activates inflammation-related pathways, we used a
conditional mouse model (Rosa26Cre-ERT2; LSL-KrasG12D) in
which KrasG12D can be induced upon tamoxifen adminstration,
leading to Cre mediated recombination from its endogenous
locus (Supplementary Fig. S1A, B). We studied, by microarray-
based analysis, BM isolated from Rosa26Cre-ERT2; LSL-KrasG12D
mice or littermate controls after induction of KrasG12D with
tamoxifen. Clustering according to genes with the annotation
“inflammation” divided WT versus KrasG12D BM into two groups
(Fig. 1a). Within the KrasG12D BM, the Nlrp3 gene was highly
significant upregulated (Fig. 1a, red arrow), and a selective clus-
tering of the gene set inflammasome from Reactome showed
upregulation of multiple NLRP3 inflammasome related genes
(Fig. 1b). In contrast to the NLRP3 inflammasome genes Nlrp3
and Pycard (Fig. 1b, red arrow), other inflammasome genes
including Casp1, GSDMD, Aim2, Nlrp1, and Nlrc4 were not
upregulated in the KrasG12D BM (Supplementary Fig. S1C). To
test for activity of the NLRP3 inflammasome in KrasG12D BM, we
quantified caspase-1 auto-maturation in unprimed cells. In
agreement with increased Nlrp3 gene expression, highly enriched
KrasG12D BMDCs (Supplementary Fig. S1D) showed increased
caspase-1 cleavage (p20 subunit detectable) compared to WT cells
(Fig. 1c, d), as well as increased IL-1β cleavage (p17 detectable)
(Fig. 1e, f), suggesting stronger inflammasome activation. Active
caspase-1 mediates pro-IL-1β maturation into its bioactive form.
IL-1β RNA transcription is initiated by TLR4/MyD88 signaling
which can be induced by LPS20. Consistently, we observed
increased amounts of IL-1β when KrasG12D BMDCs were sti-
mulated with lipopolysaccharide/adenosine-5′-triphosphate (LPS/
ATP) compared to WT BMDCs (Fig. 1g, h). The IL-1β increase
was not seen in the absence of LPS stimulation, which is in
agreement with the requirement for TLR4/MyD88/TRIFF sig-
naling for pro-IL-1β RNA transcription.
NLRP3 deficiency reverses KrasG12D-induced cytopenia. To
investigate a functional role of the NLRP3 inflammasome for the
effects induced by oncogenic KrasG12D, we next generated mice
with KrasG12D activation and NLRP3 deficiency by crossing
Rosa26Cre-ERT2; LSL-KrasG12D mice onto a NLRP3-deficient
background (Nlrp3−/−). The strain was termed Rosa26Cre-ERT2;
LSL-KrasG12D; Nlrp3−/− mice (KrasG12D; Nlrp3−/−). To avoid a
possible indirect effect of active Kras in non-hematopoietic cells,
we generated BM chimera that had either WT or KrasG12D or
KrasG12D and Nlrp3−/− in the hematopoietic compartment
(Fig. 2a). Mice with KrasG12D expression in hematopoietic system
were termed KrasG12D BM mice and mice with KrasG12D and
Nlrp3−/− in the hematopoietic system were termed KrasG12D;
Nlrp3−/− BM mice. We found that the frequency of CD45
positive cells was equal in all three groups and we could show that
the myeloablative conditioning followed by the BM transfer led to
full engraftment (Supplementary Fig. S1E, F). We then admi-
nistered tamoxifen to recipient mice to induce oncogenic
KrasG12D and later analyzed the phenotype in the peripheral
blood (PB), BM and spleen. We observed an increase in lactate
dehydrogenase (LDH) release in KrasG12D BM compared to WT
BM, while there was no difference in LDH release in KrasG12D
BM compared to KrasG12D; Nlrp3−/− BM (Supplementary Fig.
S1G). KrasG12D BM mice developed anemia (decreased hemo-
globin concentration and hematocrit) and an increase of reticu-
locytes (immature red blood cells) that were identified based on
their higher size compared to mature erythrocytes and the scat-
tered reticulum network in the cytoplasm which is visible as a
blue granular precipitate21 (Fig. 2b–e). This phenotype was not
seen in KrasG12D; Nlrp3−/− BM mice (Fig. 2b–e). In addition,
KrasG12D BM mice developed low platelet counts and giant pla-
telets were found in the peripheral blood and were not seen in
KrasG12D; Nlrp3−/− BM mice (Fig. 2f–h).
NLRP3 absence counteracts KrasG12D induced myeloproli-
feration. We then analyzed the leukocytes in more detail and
found increased frequencies of myeloid CD11b+ cells in the PB of
KrasG12D BM mice which were not seen in KrasG12D; Nlrp3−/−
BM mice (Fig. 3a, b). Neutrophil granulocytes with a dysplastic
phenotype and blasts were more frequent in KrasG12D BM mice
compared to WT or KrasG12D; Nlrp3−/− BM mice (Fig. 3c–f).
Dysplasia was identified via the presence or absence of hyperlo-
bation of the nucleus of neutrophils. Next, we asked whether
NLRP3 deficiency would also influence other KrasG12D mediated
effects. We found increased amounts of blasts and promonocytes
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Fig. 1 Oncogenic KrasG12D leads to NLRP3 inflammasome activation in murine BM cells. a The heatmap represents the expression of inflammation-
related genes in bone marrow-derived dendritic cells (BMDCs) isolated from either WT (n= 4) or KrasG12D (n= 4) mice following treatment by tamoxifen.
Color code represents the Z-score log2 intensity. b The heatmap represents the expression of inflammasomes upregulated genes from the Reactome gene
set “inflammasome” in BMDCs isolated from either WT (n= 4) or KrasG12D (n= 4) mice following treatment by tamoxifen. Color code represents the
Z-score log2 intensity. c Western blot shows the amount of caspase-1 (p20 subunit) in WT or KrasG12D BMDCs. The blot is representative for three
independent experiments. d The ratio of caspase-1 (p20 subunit)/β-actin in WT (n= 3) or KrasG12D (n= 3) BMDCs normalized to the WT. e Western blot
shows the amount of cleaved IL-1β (p17) in WT or KrasG12D BMDCs. The blot is representative for three independent experiments. f The ratio of cleaved IL-
1β (p17)/ β-actin in WT (n= 3) or KrasG12D (n= 3) BMDCs normalized to the WT. g The histogram shows mean fluorescence intensity (MFI) for IL-1β in
WT or KrasG12D BMDCs. One representative experiment from four experiments with a comparable pattern is shown. h The graph displays the fold change
of IL-1β expression as measured by flow cytometry in WT (n= 6) or KrasG12D (n= 6) BMDCs, normalized to the WT in both stimulation conditions. Pooled
data of six biological replicates per group is shown. All data are shown as mean ± SEM.
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Fig. 2 Absence of NLRP3 reverses the effects of KrasG12D in peripheral blood. a Schematic diagram summarizing the experimental plan for generating BM
chimeras that have WT BM, KrasG12D BM or KrasG12D; Nlrp3−/− BM. b The percentage of hematocrit in PB of WT (n= 10), KrasG12D (n= 15) and KrasG12D;
Nlrp3−/− (n= 10) BM mice. c The concentrations of hemoglobin in PB of WT (n= 10), KrasG12D (n= 15) and KrasG12D; Nlrp3−/− (n= 10) BM mice. d The
percentage of immature red blood cells observed in PB of WT (n= 10), KrasG12D (n= 8) and KrasG12D; Nlrp3−/− (n= 9) BM mice. e Representative PB smears
images showing the increase in immature blood cells (marked with yellow arrows) in KrasG12D BM mice, as compared to WT and KrasG12D; Nlrp3−/− BM mice
(Scale bar, 100 µm). The images are representative for three independent experiments. f Platelet counts in the PB of WT (n= 10), KrasG12D (n= 15) and KrasG12D;
Nlrp3−/− (n= 10) BM mice are shown. g Representative PB smear image showing the enlarged size of platelets in KrasG12D BM mice (Scale bar, 10 µm). h The
number of giant platelets counted in PB smears of WT (n= 10), KrasG12D (n= 15) and KrasG12D; Nlrp3−/− (n= 10) BM mice. All data are shown as mean ± SEM.
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in the BM of KrasG12D BM mice compared to WT or KrasG12D;
Nlrp3−/− BM mice (Fig. 3g). The number of blasts in the PB was
increased in KrasG12D; Nlrp3−/− BM mice compared to WT mice
(Fig. 3g). When analyzing the BM morphology, KrasG12D BM
mice exhibited hypercellularity with reduced lipid-rich adipose
cells and clusters of immature granulocytic cells (Fig. 3h, i).
Moreover, KrasG12D BM mice developed splenomegaly, which
was not seen in KrasG12D; Nlrp3−/− BM mice (Fig. 4a, b). In
agreement with this finding, splenomegaly is a disease feature of
JMML driven by KRAS activation22. In contrast to the spleen,
organs that do not belong to the hematopoietic/lymphatic system
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KRAS activation was restricted to the hematopoietic/lymphatic
system. Also, the splenic architecture comprising white pulp
lymphoid follicles with germinal centers and marginal zone areas
in WT mice was disrupted in KrasG12D BM mice but not in
KrasG12D; Nlrp3−/− BM mice (Fig. 4c, d). We found abnormal
infiltrates of myeloid progenitor cells in the spleens of KrasG12D
BM mice but not in KrasG12D; Nlrp3−/− BM mice (Fig. 4e).
Moreover, myeloid CD11b+ cells were increased in the spleens of
KrasG12D BM mice but not in KrasG12D; Nlrp3−/− BM mice
(Fig. 4f). Consistent with these findings in the spleen and BM, we
observed higher numbers of granulocytes in the PB of KrasG12D
BM mice but not in KrasG12D; Nlrp3−/− BM mice (Fig. 4g).
Conversely, the percentages of T cells of all CD45+ cells were
decreased in KrasG12D BM mice (Fig. 4h, i).
To clarify whether the NLRP3 inflammasome was active in
myeloid cells of KrasG12D BM mice, we studied cleaved caspase-1
and cleaved IL-1β (p17 detectable) concentrations in BMDCs
(enrichment purity: Supplementary Fig. S2A). In agreement with
increased NLRP3 inflammasome activation, KrasG12D BMDCs
led to increased cleaved caspase-1 (Fig. 5a, b), increased cleaved
IL-1β (p17 detectable) in cell lysates (Fig. 5c, d) and in cell-free
supernatants (Supplementary Fig. S2B), compared to WT and
KrasG12D; Nlrp3−/− BMDCs. Additionally, we observed increased
amounts of IL-1β in KrasG12D BMDCs compared to WT and
KrasG12D; Nlrp3−/− BMDCs (Fig. 5e, f, Supplementary Fig. S2C),
following stimulation. The differences observed between WT and
KrasG12D; Nlrp3−/− BMDCs indicate that KRAS does not
exclusively cause the phenotype by IL-1β release, but also by a
direct pro-proliferative effect. The IL-1β increase was not seen in
the absence of LPS stimulation, which is in agreement with the
need for TLR4/MyD88/TRIFF signaling for IL-1β RNA
transcription.
To evaluate whether the connection between oncogenic
KrasG12D and NLRP3 is cell-autonomous, we analyzed if the
myeloproliferation caused by the KRAS/NLRP3 axis in vivo
would also be active in vitro in the absence of a microenviron-
ment. We observed that proliferation of myeloid cells in vitro was
higher when the cells were derived from KrasG12D mice compared
to WT mice (Fig. 5g–i). We also found that proliferation in
BMDCs generated from KrasG12D was higher compared to
BMDCs generated from KrasG12D; Nlrp3−/− mice indicating
that NLRP3 deficiency reverses the Kras-induced phenotype
(Fig. 5i). However, proliferation in BMDCs generated from
KrasG12D; Nlrp3−/− mice was higher compared to BMDCs
generated from WT mice (Fig. 5i). These findings support the
concept that the connection between oncogenic KrasG12D and
NLRP3 is partly cell-autonomous and partly via impacting the
microenvironment. An immunosuppressive, pro-tumorigenic
role of IL-1β in the tumor microenvironment has been reported
before23.
NLRP3 inhibition reverses myeloproliferation by KrasG12D. To
study the functional role of the NLRP3/IL-1β axis, we treated
KrasG12D BM mice with the IL-1 receptor type 1 antagonist
Anakinra (recombinant IL-1RA) or the NLRP3 inhibitor
MCC950 for 4 weeks, starting 3 weeks post-tamoxifen when the
disease was established until the day before analysis. We observed
increased hematocrit and hemoglobin concentrations in KrasG12D
BM mice treated with Anakinra or MCC950 (Fig. 6a, b), com-
pared to KrasG12D BM mice treated with vehicle. In addition,
there was a decrease in the percentage of immature red blood cells
in PB of Anakinra-treated KrasG12D BM mice, compared to
vehicle-treated KrasG12D BM mice (Fig. 6c). Platelet counts
increased in KrasG12D BM mice treated with Anakinra or
MCC950 (Fig. 6d). Moreover, Anakinra or MCC950 treatment
could reverse the spleen and BM phenotype in KrasG12D recipient
mice (Fig. 6e, f). Consistent with a reduced KRAS/NLRP3/IL-1β
axis, we observed decreased amounts of IL-1β in BMDCs
(enrichment purity: Supplementary Fig. S2D) generated from
Anakinra-treated or MCC950-treated KrasG12D BM mice com-
pared to vehicle-treated KrasG12D BM mice (Fig. 6g, h). Impor-
tantly the inhibitor treatment did not lead to a depletion of a
certain cell type (Fig. 6i, Supplementary Fig. S3A, B) but only to a
mild reduction of mature neutrophils that did not reach sig-
nificance (Fig. 6j). These findings indicate that NLRP3 and IL-1R
are therapeutic targets to interfere with KRAS-driven
myeloproliferation.
Myeloproliferation is mediated via the RAC1/ROS/NLRP3
axis. To understand the mechanism by which oncogenic KRAS
leads to NLRP3 activation, we performed an unbiased gene
expression analysis of WT or KrasG12D BMDCs. We observed
increased expression of genes for Gene Ontology (GO) terms
related to NADPH oxidase, an enzyme required for the produc-
tion of extracellular/endosomal ROS (Fig. 7a). In agreement, we
found increased cellular ROS production in KrasG12D BMDCs
compared to WT (Fig. 7b, c). Blocking ROS production by PDTC
or Ebselen (enrichment purity and viability: Supplementary
Fig. S4A, B) abrogated the increased caspase-1 cleavage seen in
KrasG12D BMDCs (Fig. 7d, e).
To clarify which KRAS downstream signals activate NADPH
and NLRP3, we next used MEK-specific inhibitors, an ERK
inhibitor, PI3K-specific inhibitors and a RAC1 inhibitor and
then studied ROS production and NLRP3 inflammasome
activation. At the concentrations used the cell viability was
not affected (Supplementary Fig. S4C). We observed no change
in IL-1β expression in KrasG12D BMDCs when MEK, ERK or
PI3K were blocked by Trametinib, Selumetinib, Ulixertinib,
Buparlisib and Pictilisib (Supplementary Fig. S4D). Conversely,
caspase-1 cleavage and IL-1β expression were reduced in
Fig. 3 NLRP3 deficiency reverses myeloproliferation observed in KrasG12D mice. a The plot shows the percentage of CD11b+ cells in PB of WT, KrasG12D
and KrasG12D; Nlrp3−/− BM mice. One representative experiment from three experiments is shown. b The percentage of CD11b+ in PB of WT (n= 10),
KrasG12D (n= 15) and KrasG12D; Nlrp3−/− (n= 10) BM mice is shown. c Representative PB smears images of WT, KrasG12D and KrasG12D; Nlrp3−/− BM mice
showing neutrophil granulocytes with a dysplastic phenotype in KrasG12D BM mice which is absent in WT and KrasG12D; Nlrp3−/− BM mice (Scale bar, 10
µm).. Dysplasia diagnosis was based on hyperlobation of the nucleus. d The number of dysplastic neutrophils counted in PB isolated from WT (n= 6),
KrasG12D (n= 6) and KrasG12D; Nlrp3−/− (n= 6) BM mice is shown. The counts represent percentage of 100 analyzed cells. e Representative PB smears
image of a KrasG12D mouse showing a blast which is absent in WT and KrasG12D; Nlrp3−/− BM mice (Scale bar, 10 µm). The image is representative for three
independent experiments. f The number of blast cells counted in PB isolated from WT (n= 6), KrasG12D (n= 6) and KrasG12D; Nlrp3−/− (n= 6) BM mice.
The counts represent percentage of 100 analyzed cells. g The number of blast cells counted in BM isolated fromWT (n= 6), KrasG12D (n= 6) and KrasG12D;
Nlrp3−/− (n= 6) BM mice. The counts represent percentage of 100 analyzed cells. h, i Representative H&E stained BM images of WT, KrasG12D and
KrasG12D; Nlrp3−/− BM mice showing (h) hypercellular BM with reduced fat vacuoles (marked with yellow arrows) (Scale bar, 50 µm). and (i) clusters of
immature neutrophils (marked with yellow arrows) in KrasG12D BM mice compared to normal BM phenotype observed in WT and KrasG12D; Nlrp3−/− BM
mice (Scale bar, 10 µm). The images are representative for three independent experiments. All data are shown as mean ± SEM.
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Fig. 4 KrasG12D induces splenomegaly which is reversed in KrasG12D; Nlrp3 −/− BM mice. a Representative image displaying spleen sizes of WT, KrasG12D
and KrasG12D; Nlrp3−/− BM mice at the end of the experiment. b Measurements of spleen weight of WT (n= 10), KrasG12D (n= 15) and KrasG12D; Nlrp3−/−
(n= 10) BM mice. c The number of spleen follicles counted in spleens isolated from WT (n= 10), KrasG12D (n= 15) and KrasG12D; Nlrp3−/− (n= 10) BM
mice, per 1 high power field (HPF). d, e Photomicrographs of H&E stained splenic tissue sections of WT, KrasG12D and KrasG12D; Nlrp3−/− BM mice showing
(d) disrupted splenic architecture in KrasG12D (Scale bar, 100 µm) compared to WT (Scale bar, 100 µm) and KrasG12D; Nlrp3−/− (Scale bar, 50 µm) BM
mice which show typical normal follicles (marked with yellow arrows) with preserved mantle zones. (e) Abnormal infiltrates of myeloid progenitor cells
predominantly in the splenic red pulp of KrasG12D but not in KrasG12D; Nlrp3−/− BM mice (Scale bar, 20 µm). d The yellow arrows indicate spleen follicles.
e The yellow arrows indicate myeloid progenitor cells. f The percentage of CD11b+ cells in spleens of WT (n= 10), KrasG12D (n= 15) and KrasG12D; Nlrp3−/−
(n= 10) BM mice. g Shown is the abundance of granulocytes in PB of WT (n= 10), KrasG12D (n= 15), and KrasG12D; Nlrp3−/− (n= 10) BM mice. h The plot
shows the percentage of CD90.2+ in spleens of WT, KrasG12D and KrasG12D; Nlrp3−/− BM mice. One representative experiment from three experiments is
shown. (i) The percentage of CD90.2+ in spleens of WT (n= 10), KrasG12D (n= 15), and KrasG12D; Nlrp3−/− (n= 10) BM mice. All data are shown as
mean ± SEM.
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Fig. 5 Increased NLRP3 inflammasome activation by KrasG12D is reversed the absence of NLRP3. a Western blot shows the amount of caspase-1
(p20 subunit) in BMDCs generated from WT, KrasG12D and KrasG12D; Nlrp3−/− BM mice. The blot is representative for three independent experiments. b The
ratio of caspase-1 (p20 subunit)/β-actin in BMDCs generated from WT (n= 3), KrasG12D (n= 3), and KrasG12D; Nlrp3−/− (n= 3) BM mice, normalized to WT.
cWestern blot shows the amount of cleaved IL-1β (p17) in BMDCs generated fromWT, KrasG12D and KrasG12D; Nlrp3−/− BMmice. The blot is representative for
three independent experiments. d The ratio of cleaved IL-1β (p17)/β-actin in BMDCs generated fromWT (n= 3), KrasG12D (n= 3) and KrasG12D; Nlrp3−/− (n=
3) BM mice, normalized to WT. e The histogram shows mean fluorescence intensity (MFI) for IL-1β in BMDCs generated from WT, KrasG12D and KrasG12D;
Nlrp3−/− BM mice. One representative experiment from three experiments is shown. f The graph displays the fold change of IL-1β expression as measured by
flow cytometry in BMDCs generated from WT (n= 10), KrasG12D (n= 15) and KrasG12D; Nlrp3−/− (n= 10) BM mice, normalized to the WT in both stimulation
conditions. g The histogram shows mean fluorescence intensity (MFI) for EdU in BMDCs generated from WT, KrasG12D or KrasG12D; Nlrp3−/− mice. One
representative experiment from two experiments is shown. h The graph displays the fold change of cell proliferation measured by EdU incorporation in BMDCs
generated from WT (n= 6), KrasG12D (n= 6), or KrasG12D; Nlrp3−/− (n= 6) mice, normalized to the WT. i The graph displays the number of cells counted
following BMDCs generation using isolated BM from WT (n= 6), KrasG12D (n= 6), or KrasG12D; Nlrp3−/− (n= 6) mice. All data are shown as mean ± SEM.
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KrasG12D BMDCs when RAC1 was blocked (Fig. 7f–h).
Consistent with a role for RAC1, we observed increased levels
of active RAC1-GTP in KrasG12D BMDCs (Fig. 7i, j). RAC1
inhibition, but not MEK, ERK or PI3K-inhibition reduced ROS
production by KrasG12D BMDCs (Fig. 7k, Supplementary
Fig. S4E).
NLRP3 inflammasome activation in human KRAS-mutant
(Krasmut) leukemia cells. To determine whether the observations
made in mouse cells were also seen in human cells, we isolated
PBMCs of AML, JMML or CMML patients with KRAS mutations
(Krasmut) and gated on CD11b+ cells (Supplementary Fig. S5A).
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Krasmut), we observed increased cleaved caspase-1 in Krasmut
PBMCs (Fig. 8a, b), indicating increased NLRP3 inflammasome
activity in human Krasmut cells compared to non-mutant cells. In
agreement with inflammasome activation, we also observed
increased IL-1β production in human Krasmut cells compared to
non-mutant cells in JMML, AML, and CMML (Fig. 8c–g). The
cell number and phenotype was not affected by the stimulation
with LPS (Supplementary Fig. S5B).
To determine if the KRAS mutations were found in CD11b
positive cells, we sorted for these cells, and analyzed the resulting
DNA using targeted Next-Generation Sequencing (NGS) and
digital droplet PCR (ddPCR) for the respective KRAS mutations.
We could show that the KRAS mutations were found in CD11b+
sorted cells at a high variant allele frequency (VAF; 45%, 49% in
representative samples, Supplementary Fig. S5C-E). In addition,
we found increased cleaved caspase-1 in human Krasmut CMML
cells compared to non-Krasmut cells (Fig. 8h, i). CMML
samples with NRAS mutations (Nrasmut) displayed only a small
increase of IL-1β (Supplementary Fig. S5F).
Increased ROS production in human Krasmut myeloid leuke-
mia cells. Comparable to the observations made in mice, we
found that ROS production was increased in human Krasmut cells
compared to non-Krasmut cells derived from AML patients in the
cytoplasm (Fig. 9a, b) and in the mitochondria (Fig. 9c, d).
Blocking ROS production by PDTC or Ebselen reduced IL-1β
production (Fig. 9e), and also abrogated the increased caspase-1
cleavage seen in Krasmut JMML PBMCs (Fig. 9f, g). Increased
ROS production was also seen in Krasmut cells, but not Nrasmut
cells, from CMML patients compared to non-Krasmut CMML
cells (Fig. 9h, i, Supplementary Fig. S5G). Blocking ROS pro-
duction by PDTC or Ebselen reduced IL-1β production in CMML
patient Krasmut PBMCs (Fig. 9j). In addition, and similar to our
findings in murine models, blocking RAC1 in Krasmut cells, but
not Nrasmut cells, from CMML patients caused a reduction of IL-
1β expression and ROS production (Fig. 9k, l, Supplementary
Fig. S5H, I).
These observations in patient samples show that the KRAS/
ROS/NLRP3/IL-1β axis was also active in human AML, CMML
and JMML cells, which is in agreement with our observations in
mouse models.
Our findings indicate that oncogenic KRAS leads to RAC1
activation, causing NADPH activation, resulting in ROS produc-
tion, which in turn activates the NLRP3 inflammasome causing
cleavage of caspase-1 and IL-1β production (Fig. 10; proposed
model).
Discussion
Improving the treatment of JMML, CMML, and KRAS-mutant
AML is still a major unmet clinical need. Conventional che-
motherapy in JMML has little effect24 and the probability of
event-free survival at 5 years is only 50% after allogeneic
hematopoietic cell transplantation (allo-HCT)25. Similarly,
allo-HCT remains the only curative option for patients with
CMML, with an overall survival at 3 years of 32%12. A major
clinical feature of patients with JMML are inflammatory
symptoms including hepatosplenomegaly in greater than 90%,
lymphadenopathy in 76%, pallor in 64%, fever in 54%, skin rash
in 36%22,26. Also in CMML hepatomegaly, splenomegaly and
features of myeloproliferation, such as fatigue, symptoms from
organomegaly, night sweats, weight loss and cachexia have been
reported12. The pathomechanism causing these symptoms in
KRAS-mutant myeloid neoplasms was not fully elucidated.
Here we report that multiple inflammation-related genes are
upregulated upon oncogenic KRAS activation in myeloid cells.
A major inflammatory pathway we identified was the NLRP3/
caspase-1/IL-1β axis. This is consistent with previous reports
showing that IL-1β was increased in JMML27,28. These reports,
however, did not clarify the mechanism underlying the
increased IL-1β production, because the role of the inflamma-
some for IL-1β activity was unknown at this time. Our work
identifies a critical role of the NLRP3 inflammasome in
KrasG12D induced inflammation, as the hematological pheno-
type caused by oncogenic KrasG12D expression is reversed by
NLRP3 deficiency. Our studies delineate that oncogenic KRAS
activates RAC1 which in turn leads to the production of ROS.
The impaired hematopoiesis and splenomegaly that we
observed when the NLRP3/IL-1β axis was active upon KRAS
activation is very similar to the hepatosplenomegaly and pan-
cytopenia reported in patients with activating mutations of
NLRP3 that suffer from Cryopyrin-associated periodic syn-
drome (CAPS)29. In agreement with our findings, CAPS
patients experience an improvement of their symptoms upon
IL-1β blockade29. The regulation of cytokine production via
oncogene/growth factor receptor activation has been previously
reported for FLT3-ITD signaling blocking IL-15 production14,
promoting lytic cell death and inflammasome activation30,
cMYC induced IL-1031 and TNF-α32 production and EGFR
induced IL-6 production33. The production of these cytokines
may shape the tumor microenvironment in a favorable fashion
for tumor cells. It is possible that besides IL-1β, also IL-18
plays a role because attenuating IL-1β with Anakinra produces
a less robust protective effect compared to blocking NLRP3.
Fig. 6 IL-1R- or NLRP3- inhibition in KrasG12D mice leads to reduced myeloproliferation. a The percentage of hematocrit in PB of vehicle-treated KrasG12D
(n= 15), Anakinra-treated KrasG12D (n= 10) or MCC950-treated KrasG12D (n= 15) BM mice. Both Anakinra and NLRP3 inhibitor (MCC950) treatment
started 3 weeks post-tamoxifen and ended a day before sacrificing the mice (treatment was in total for 4 weeks). b The concentrations of hemoglobin in PB
of vehicle-treated KrasG12D (n= 15), Anakinra-treated KrasG12D (n= 10) or MCC950-treated KrasG12D (n= 15) BM mice. c The percentage of immature red
blood cells observed in PB of vehicle-treated KrasG12D (n= 15), Anakinra-treated KrasG12D (n= 10) or MCC950-treated KrasG12D (n= 15) BM mice. d Shown
are the number of platelets in PB of vehicle-treated KrasG12D (n= 15), Anakinra-treated KrasG12D (n= 10) or MCC950-treated KrasG12D (n= 15) BM mice.
e The number of blast cells counted in BM isolated from vehicle-treated KrasG12D (n= 5), Anakinra-treated KrasG12D (n= 6) or MCC950-treated KrasG12D
(n= 15) BM mice. The counts represent percentage of 100 analyzed cells. f The number of spleen follicles counted in spleens isolated from vehicle-treated
KrasG12D (n= 5), Anakinra-treated KrasG12D (n= 6) or MCC950-treated KrasG12D (n= 15) BM mice, per 1 high power field (HPF). g The histogram shows
mean fluorescence intensity (MFI) for IL-1β in BMDCs of vehicle-treated KrasG12D, Anakinra-treated KrasG12D or MCC950-treated KrasG12D BM mice. One
representative experiment from three experiments is shown. h The graph displays the fold change of IL-1β expression as measured by flow cytometry in
BMDCs of vehicle-treated KrasG12D (n= 15), Anakinra-treated KrasG12D (n= 10) or MCC950-treated KrasG12D (n= 15) BM mice, normalized to vehicle-
treated KrasG12D in both stimulation conditions. i FlowSOM-guided metaclustering of CD45+ BM cells (gated on live/single cells/CD45+) per condition:
vehicle-treated KrasG12D (n= 4), Anakinra-treated KrasG12D (n= 5) or MCC950-treated KrasG12D (n= 5) BM mice. j Frequency of FlowSOM-guided mature
neutrophils cluster among CD45+ BM cells in vehicle-treated KrasG12D (n= 4), Anakinra-treated KrasG12D (n= 5) or MCC950-treated KrasG12D (n= 5) BM
mice. All data are shown as mean ± SEM.
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Regarding the relevant cell type, the scenario that activation of
NLRP3 in non-leukemic cells contributes as a driver of the
disease is conceivable.
We also clarify the mechanism by showing that KRAS-induced
ROS production leads to NLRP3 activation. Previous work had
shown that ROS can activate NLRP334. Functional inhibition of
NADPH oxidase-derived ROS prevented ATP-induced caspase-1
activation and IL-1β production in alveolar macrophages35. Con-
sistently we had observed NADPH gene expression being increased
upon KRAS activation and that blocking ROS production reduced
caspase-1 activation and IL-1β cleavage in KRAS-mutant mouse and
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Our findings support the concept that oncogenic KRAS does
not only act via its oncogenic driver function but also enhances
activation of the NLRP3/IL-1β axis, which explains the clinical
features of JMML and CMML patients suffering from
inflammation-related symptoms. Even when NLRP3 inhibition or
IL-1R blockade could not eliminate the malignant clone, this
therapy could reduce the symptoms of patients such as massive
splenomegaly, unexplained fever and failure to thrive, which
would be a major benefit for the patients and bring them into a
condition that is more stable before undergoing the potentially
curative allo-HCT.
In summary, the data suggest NLRP3 and IL-1R inhibition as a
strategy for the treatment of KRAS-driven hematological
malignancies.
Methods
Human subjects. Human sample collection and analysis were approved by the
Institutional Ethics Review Board of the Medical center, University of Freiburg,
Germany (protocol numbers 10024/13, 26/11, 509/16). Written informed consent
was obtained from each patient. All analysis of human data was carried out in
compliance with relevant ethical regulations. The characteristics of patients are
listed in Supplementary Tables S1–S3.
Mice. C57BL/6 (H-2Kb, Thy-1.2) were purchased from Janvier Labs (France).
Rosa26-Cre-ERT2 transgenic36 and LSL-KrasG12D knock-in mice37 were main-
tained on a C57BL/6N background and mated to generate Rosa26-Cre-ERT2; LSL-
KrasG12D animals. As Kras deficiency is embryonic lethal and because the LSL-
KrasG12D knock-in allele prevents expression of oncogenic Kras prior to Cre
mediated recombination, all LSL-KrasG12D carrying mice retained a wildtype Kras
allele. Nlrp3−/− mice were obtained from the local stock at the animal facility of
University Medical Center Freiburg. Rosa26-Cre-ERT2; LSL-KrasG12D were bred to
Nlrp3−/− mice (both on C57BL/6 background) in the animal facility at the Uni-
versity of Freiburg, to generate the strain termed Rosa26-Cre-ERT2; LSL-KrasG12D;
Nlrp3−/−. Mice were bred and housed under specific pathogen-free (SPF) condi-
tions in the animal facilities of University Medical Center Freiburg (ZKF, Neuro-
zentrum and IMMZ) and were used between 8 and 16 weeks of age at the time of
the experiments. All mouse experiments were approved by the Federal Ministry for
Nature, Environment and Consumers’ Protection of the state of Baden-Würt-
temberg, Germany (Protocol numbers: G-17/049, G-17/093, X-14/07H, X-15/09H,
X-15/10A, X-18/10C).
Isolation of patient-derived peripheral blood mononuclear cells (PBMCs).
PBMCs were isolated from patients’ blood by Ficoll gradient centrifugation,
according to the manufacturer’s protocol (Sigma-Aldrich), and frozen in Fetal Calf
Serum (FCS) with 10% Dimethyl sulfoxide (DMSO). Once thawed, cells were
plated in 6-well plates at 0.5 × 106 cells per well, and left for 24 h to recover. If
stated, PBMCs were stimulated with 200 ng/ml of LPS followed by 5 mM of ATP,
with a minimum of 4 h in between. Cells were gated on CD11b+ cells.
Bone marrow transplantation (BMT) and generation of BM chimera. Recipient
mice were lethally irradiated with split doses of 5 Gy and 4.5 Gy (137 Cs source),
with a minimum period of 4 h in between, followed by retro-orbital venous plexus
injection of 5 × 106 donor BM cells. Peripheral blood (PB) samples were obtained
at different time points, and PB counts were performed using the scil Vet abc
analyzer (Henry Schein). For BMT studies, the experiment was performed 3 times
and pooled data of the indicated number of biological replicates per group
is shown.
Treatments. Tamoxifen free base (Sigma T5648) was prepared as 20 mg/ml in
corn oil and administrated to mice at a single dose of 1 mg per mouse, via oral
gavage. The administration of tamoxifen induces nuclear translocation of Cre-
ERT2, causing the deletion of the LSL elements in Cre-ERT2, KrasG12D mice37. A
proof of successful recombination was determined using the polymerase chain
reaction (PCR) protocol established by the Jacks laboratory (https://jacks-lab.mit.
edu/protocols/genotyping/kras_cond) and Western blotting (Supplementary
Fig. S1A, B). To assess the role of NLRP3 and IL-1 (IL-1 α and ß) in the disease
phenotype, mice were treated with an IL-1 type 1 receptor antagonist or a NLRP3
inflammasome inhibitor. Anakinra (Kineret®; Swedish Orphan Biovitrum - sobi)
was administered once daily via subcutaneous injection at a dose of 10 mg/kg.
MCC95038 was administered once daily via intraperitoneal injection at a dose of
30 mg/kg. Mice from the vehicle group were treated with phosphate-buffered saline
(PBS). Both Anakinra and NLRP3 inhibitor (MCC950) treatment started 3 weeks
post-tamoxifen and ended one day before sacrificing the mice (treatment was in
total for 4 weeks).
Generation of bone marrow-derived dendritic cells (BMDCs) and stimulation.
Bone marrow cells were cultured at 6 × 106 cells in the presence of 40 ng/ml GM-
CSF in 10 ml of RPMI 1640 medium (Gibco) in 10 cm dishes. On day 3, 10 ml of
fresh medium containing 40 ng/ml GM-CSF was added. On day 7, 10 ml medium
was replaced with fresh medium containing 40 ng/ml GM-CSF. Cells were used on
days 7 or 8 with a CD11c+ purity of >80%, as determined by flow cytometry. If
stated, BMDCs were stimulated with 200 ng/ml of Lipopolysaccharide (LPS, Sigma-
Aldrich) for 4 h, followed by 5 mM of Adenosine 5′-triphosphate disodium salt
(ATP; Sigma A7699-1G) for 30–60 min. For ELISA and colorimetric assay, BMDCs
were primed with 200 ng/ml E.coli K12 ultra-pure LPS (InvivoGen) for 3–9 h and
subsequently stimulated with either 5 µM of Nigericin (Sigma-Aldrich) for 90 min,
5 mM of ATP for 90 min or left without secondary stimulus. All stimulations were
performed at least in biological and technical triplicates.
Immunohistochemical and histological analysis. Tissue sections of tibia, femur,
and spleen were collected at the terminal point of the experiment, fixed in 4%
paraformaldehyde for 12 to 16 h at 4 °C and washed in 70% ethanol. Tissues were
embedded in paraffin and cut into 5-μm sections, followed by the standard pro-
tocol of Hematoxylin/Eosin (H/E) staining. Blood smears were stained with Pap-
penheim stain. The results were assessed, graded and quantified by an investigator
blinded to the experimental groups.
Flow cytometry. The fluorochrome-conjugated antibodies mAbs (Clone) used for
flow cytometric analysis are shown in Supplementary Table S4. To examine cell
viability and exclude dead cells, the LIVE/DEAD Fixable Dead Cell Stain kit
(Molecular Probes) or the Zombie NIR Fixable Viability kit (Biolegend) were used.
For intracellular staining, the BD Cytofix/Cytoperm kit (BD Biosciences) was used
following the manufacturer’s protocol. Data were acquired on a BD LSR Fortessa
flow cytometer (BD Bioscience) and analyzed using the FlowJo (Flowjo 10.4, LLC)
software. Multiparameter high-dimensional data was acquired on a FACSSymph-
ony (BD Bioscience) and compensated in FlowJo (V10.6), then live, single CD45+
cells were exported and analyzed using the R environment39. Data were processed
for FlowSOM clustering40. For dimensionality reduction the UMAP package was
used41.
Fig. 7 KrasG12D causes inflammasome activation RAC1 and reactive oxygen species (ROS) production. a The heatmap shows genes for upregulated GO
terms for NADPH in BMDCs generated from either WT (n= 4) or KrasG12D (n= 4) mice following treatment by tamoxifen. Color code represents the Z-
score log2 intensity. b The histogram shows mean fluorescence intensity (MFI) for H2DCF-DA in WT or KrasG12D BMDCs. c The graph displays the fold
change of H2DCF-DA expression as measured by flow cytometry in WT (n= 9) and KrasG12D (n= 9) BMDCs, normalized to WT in both stimulation
conditions. d Western blot shows the amount of caspase-1 (p20 subunit) in BMDCs isolated from KrasG12D mice treated with DMSO, Ebselen or PDTC,
after stimulation with 200 ng/ml LPS and 5mM ATP. The blot is representative for two independent experiments. e The ratio of caspase-1 (p20 subunit)/
β-actin in KrasG12D BMDCs treated with DMSO (n= 3), Ebselen (n= 3) or PDTC (n= 3), normalized to DMSO-treated KrasG12D BMDCs. f Western blot
shows the amount of caspase-1 (p20 subunit) in BMDCs generated from KrasG12D mice treated with DMSO, 50 µM or 100 µM of RAC1 inhibitor NSC
23766, after stimulation with 200 ng/ml LPS and 5mM ATP, normalized to DMSO-treated KrasG12D BMDCs. The blot is representative for two
independent experiments. g The ratio of caspase-1 (p20 subunit)/Vinculin in KrasG12D BMDCs treated with DMSO (n= 3), 50 µM (n= 3) or 100 µM (n=
3) of RAC1 inhibitor NSC 23766, normalized to DMSO-treated KrasG12D BMDCs. h The graph displays the fold change of IL-1β expression as measured by
flow cytometry in KrasG12D BMDCs treated with DMSO (n= 6), 50 µM (n= 6) or 100 µM (n= 6) of RAC1 inhibitor NSC 23766, after stimulation with 200
ng/ml LPS and 5mM ATP, normalized to DMSO-treated KrasG12D BMDCs. i Western blot shows the amount of active RAC1-GTP in BMDCs generated
from WT or KrasG12D mice. j The ratio of active RAC1-GTP/Vinculin in BMDCs generated from WT (n= 3) or KrasG12D (n= 3) BM, normalized to WT.
k The graph displays the fold change of H2DCF-DA expression in BMDCs generated from KrasG12D mice, treated with DMSO (n= 6), 50 µM (n= 6) or
100 µM (n= 6), normalized to DMSO-treated KrasG12D BMDCs. All data are shown as mean ± SEM.
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Fig. 8 KRAS-mutant human leukemia cells exhibit increased NLRP3 inflammasome activation. a Western blot shows the amount of caspase-1
(p20 subunit) in PBMCs isolated from patients with a KRAS mutation (Krasmut) or without a KRAS mutation (non-Krasmut). The blot is representative for
four independent experiments. b The ratio of caspase-1 (p20 subunit)/β-actin in Krasmut (n= 8) or non-Krasmut (n= 8) patients’ PBMCs normalized to
non-Krasmut. c The histogram shows mean fluorescence intensity (MFI) for IL-1β in CD11b+ cells of Krasmut JMML or non- Krasmut AML patients. One
representative experiment from four experiments with is shown. d–e The graphs display the fold change of IL-1β expression as measured by flow cytometry
in (d) Krasmut JMML (n= 9) and (e) Krasmut AML (n= 11), compared to non-Krasmut AML patients’ PBMCs (n= 22), normalized to non-Krasmut. (f) The
histogram shows mean fluorescence intensity (MFI) for IL-1β in CD11b+ cells of Krasmut or non-Krasmut CMML patients’ cells. One representative
experiment from four experiments is shown. (g) The graph displays MFI fold change of IL-1β expression as measured by flow cytometry in Krasmut (n= 5)
and non-Krasmut (n= 13) CMML patients’ PBMCs, normalized to non-Krasmut. h Western blot shows the amount of caspase-1 (p20 subunit) in PBMCs
isolated from CMML patients with a KRAS mutation (Krasmut) or without a KRAS mutation (non-Krasmut). i The ratio of caspase-1 (p20 subunit)/Vinculin
in Krasmut (n= 4) or non-Krasmut (n= 4) CMML patients’ PBMCs normalized to non-Krasmut.
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Western blot. Cells were lysed in radioimmunoprecipitation assay buffer (Santa
Cruz Biotechnology) supplemented with Phosphatase Inhibitor Cocktail 2 (Sigma-
Aldrich) and protein concentrations were determined using the Pierce BCA Pro-
tein Assay Kit (Life Technologies). Cell lysates prepared for SDS-PAGE using
NuPAGE™ LDS sample buffer and NuPAGE™ sample reducing agent (Invitrogen).
Supernatant samples from cell-free supernatants were prepared using sample buffer
containing SDS and Dithiothreitol (DTT). The primary antibodies were used
against caspase-1 (p20) (mouse; Adipogen #AG-20B-0042-C100), caspase-1 (p20)
(human; Adipogen #AG-20B-0048-C100), cleaved-IL-1β (Asp117) (Cell Signaling
Technology #52718), IL-1β (R&D Systems #AF-401), Ras (Abcam #52939), active
Rac1 (NewEast Biosciences #26903). β-actin (Cell Signaling Technology #4970, or
Santa Cruz Biotechnology #sc-47778) or Vinculin (Cell Signaling Technology
#13901) were used as loading controls. As a secondary antibody, horseradish
peroxidase (HRP)-linked anti-rabbit IgG or anti-mouse IgG were used (#7074 and
#7076S Cell Signaling Technology). The blot signals were detected using Wester-












































































































































































































































































































































































































4 p < 0.0001
Non-Krasmut AML (n = 10)
Krasmut AML (n = 11)
Non-Krasmut AML (n = 11)
Krasmut AML (n = 16)
+ LPS/ATPUnstimulated
Non-Krasmut CMML (n = 13)
Krasmut CMML (n = 5)
Krasmut CMML (n = 5)
Krasmut CMML +
RAC1 inhibitor (n = 5)
Krasmut CMML (n = 5)
Krasmut CMML +
RAC1 inhibitor (n = 5)
Krasmut (n = 5)
Krasmut + PDTC (n = 5)
Krasmut + Ebselen (n = 5)
Krasmut (n = 3)
Krasmut + PDTC (n = 3)
Krasmut + Ebselen (n = 3)
Krasmut (n = 5)
Krasmut + Ebselen (n = 5)
Krasmut + PDTC (n = 5)
p < 0.0001
p < 0.0001
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3.2.0 (Intas Science Imaging Instruments GmbH) and quantified using ImageJ
(NIH) software.
Reactive oxygen species (ROS) analysis and inhibition. 2′, 7′-dichloro-
fluorescein diacetate (H2DCF-DA; Sigma D6883) was used to detect cellular ROS.
One vial was dissolved in dimethyl sulfoxide (DMSO) to prepare 20 mg/ml stock
solution. Briefly, cells were pelleted and resuspended in 1.16 µg/ml of H2DCF-DA
and incubated at 37 °C in the dark for 30 min. The cells were pelleted and resus-
pended in fresh medium along with stimulus and incubated at 37 °C in the dark for
60 min. After washing, cells were stained to their corresponding surface antigen at
4 °C in the dark for 20 min and washed before acquisition on flow cytometer.
MitoSOXTM red reagent (Thermofisher M36008) was used as an indicator of
mitochondrial ROS (mtROS) in live cells. One vial was dissolved in DMSO to make
a 5 mM MitoSOXTM stock solution. Cells were incubated in 5 µM MitoSOXTM in
HBSS/Ca2+/Mg2+ solution (Gibco 14025) at 37 °C for 30 min. ROS signal was
measured with a BD LSR Fortessa flow cytometer and analyzed using FlowJo
software. For inhibition of ROS, 30 μM of Ebselen (Enzo Life Sciences), 50 μM
ammonium pyrrolidinedithiocarbamate (PDTC; Enzo Life Sciences) or DMSO as a
control, were added 2.5–3 h after priming with LPS and 20–30 min before stimu-
lation with ATP.
Microarray analysis. RNA was isolated from BMDCs using the RNeasy Mini Kit
(Qiagen). RNA quality was assessed by Agilent 2100 Bioanalyzer (Agilent 141
Technologies). RNA samples with an RNA integrity number (RIN) greater than 8
were further processed. Affymetrix Clariom S Mouse arrays were normalized using
Single-Channel Array Normalization and exon expression summarized to the gene
level using the R/Bioconductor package pd.clariom.s.mouse. Differential gene
expression analysis between KrasG12D BM versus WT was calculated using the R/
Bioconductor limma package with p-values corrected for multiple testing using
Benjamini & Hochberg. Gene set enrichment analysis (GSEA) was performed using
the R/Bioconductor package GAGE which tests for significant differential regula-
tion of a gene set instead of individual genes. The complete gene expression data
are available in the GEO repository under the access ID GSE131885 (https://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?&acc=GSE131885).
Ras downstream effector pathways inhibition. To delineate the role of Ras
effector pathways leading to NLRP3 activation, MEK-specific inhibitors (Trametinib
(GSK1120212) and Selumetinib (AZD6244); Selleckhem S2673 and S1008), an ERK
inhibitor (Ulixertinib (BVD-523); Selleckhem S7854), PI3K-specific inhibitors
(Buparlisib (BKM120) and Pictilisib (GDC-0941); Selleckhem S2247 and S1065) and
a Rac1 inhibitor (NSC 23766; Tocris Bioscience 2161) were used. DMSO was used as
a control. In brief, BMDCs generated from KrasG12D BM mice were treated with the
inhibitors or DMSO as a control with the indicated concentrations and times, and
later analyzed by flow cytometry or lysed for western blot.
Proliferation analysis. On day 7, the number of BMDCs generated from WT or
KrasG12D mice was counted per 10 cm dish. Biological replicates each mouse was
considered, and the average was taken. For the proliferation analysis, the Click-iT™
EdU Pacific Blue™ Flow Cytometry Assay kit (Invitrogen™; C10418) was used,
following the manufacturer’s protocol. Briefly, 10 µM of EdU was added to the
culture medium and incubated for 1–2 h. After cells were harvested and washed
with 1% BSA in PBS, extracellular staining proceeded. Following, cells were fixed
using the Click-iT™ fixative for 15 min at room temperature, and subsequent
washes were performed using the 1X Click-iT™ saponin-based permeabilization
and wash reagent. Lastly, cells were incubated for 30 min at room temperature
protected from light with the Click-iT™ reaction cocktail composed of CuSO4,
Pacific Blue dye, reaction buffer additive and PBS, following the manufacturer’s
instructions. Cells were later analyzed by flow cytometry.
Fig. 9 The KRAS/RAC1/ROS/NLRP3 axis is active in human leukemia cells. a The histogram shows mean fluorescence intensity (MFI) for H2DCF-DA in
CD11b+ cells of AML patients with a KRAS mutation (Krasmut) or without a KRAS mutation (non-Krasmut). b The graph displays MFI fold change of H2DCF-DA
expression in Krasmut (n= 11) and non-Krasmut (n= 10) AML patient cells, normalized to non-Krasmut in both stimulation conditions. c The histogram shows MFI
for MitoSOX in Krasmut or non-Krasmut AML patients cells. d The graph displays MFI fold change of MitoSOX expression in Krasmut (n= 16) and non-Krasmut (n
= 11) patient cells, normalized to non-Krasmut in both stimulation conditions. e The graph displays MFI fold change of IL-1β expression in Krasmut JMML patients
cells, treated with DMSO (n= 5), Ebselen (n= 5) or PDTC (n= 5), normalized to DMSO-treated Krasmut. f Western blot shows the amount of caspase-1
(p20 subunit) in PBMCs isolated from Krasmut JMML patients treated with DMSO, Ebselen or PDTC after stimulation with 200 ng/ml LPS and 5mMATP. g The
ratio of caspase-1 (p20 subunit)/β-actin in Krasmut PBMCs derived from JMML patients, treated with DMSO (n= 3), Ebselen (n= 3) or PDTC (n= 3),
normalized to DMSO-treated Krasmut cells. h The histogram shows MFI for H2DCF-DA in Krasmut or non-Krasmut CMML patients cells. i The graph displays MFI
fold change of H2DCF-DA expression in Krasmut (n= 5) and non-Krasmut (n= 13) CMML patients cells, normalized to non-Krasmut in both stimulation
conditions. j The graph displays MFI fold change of IL-1β expression in Krasmut CMML patients cells, treated with DMSO (n= 5), Ebselen (n= 5) or PDTC (n=
5), normalized to DMSO-treated Krasmut cells. k The graph displays MFI fold change of IL-1β expression in Krasmut CMML patients cells, treated with DMSO (n
= 5) or 100 µM of RAC1 inhibitor NSC 23766 (n= 5), after stimulation with 200 ng/ml LPS and 5mM ATP, normalized to DMSO-treated Krasmut. l The graph
displays MFI fold change of H2DCF-DA expression in Krasmut CMML patients cells, treated with DMSO (n= 5) or 100 µM of RAC1 inhibitor NSC 23766 (n= 5),

























Fig. 10 Proposed model. The scheme shows the proposed mechanism. Oncogenic KRAS leads to NLRP3/ASC transcription and RAC1-mediated production of
reactive oxygen species (ROS). This licenses the NLRP3 inflammasome and activates the inflammasome by ROS leading to caspase-1 activation, ASC recruitment
and consecutively to the release of bioactive IL-1β. The KRAS/NLRP3/IL-1β axis can be inhibited by blocking IL-1R or by inhibiting the NLRP3 inflammasome.
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Cell isolation and DNA extraction. Using fluorescence-activated cell sorting, the
CD11b+ cell population was sorted from PBMCs previously isolated from Krasmut
patients (BD FACSAria™ III, BD Biosciences). Cells were lysed using RLT plus lysis
buffer (Qiagen) and DNA extraction was performed on a QIAsymphony robot
(Qiagen).
Targeted Next Generation Sequencing (NGS). The Illumina TruSight Tumor 15
and TruSight Myeloid Panels were used for targeted resequencing and processed as
described by the manufacturer (Illumina Inc.). Sequencing libraries were sequenced
paired-end on an Illumina NextSeq 550 with 2 × 150 base reads and FASTQ-files
were further analyzed with the SeqNext software (JSI Medical Systems). We used a
significance threshold of 3% for the detection of missense mutations, with a
minimum coverage of 500 reads and 50 reads per variant.
Digital droplet polymerase chain reaction (ddPCR). ddPCR was used to validate
selected mutations in KRAS (G12V, G12A). The ddPCR reaction volume was 20 µL
and composed of 10 µL of dPCR supermix for probes (Bio-Rad Laboratories
GmbH), 900 nmol/L of each primer and 250 nmol/L probes. Each reaction mixture
was partitioned into approximately 20,000 droplets using a QX200 automated
droplet generator (Bio-Rad Laboratories GmbH) and then cycled under set con-
ditions. Cycled droplets were read in the QX 200 droplet-reader and the analysis of
the data was performed using the QuantaSoft analysis software (Version 1.0, Bio-
Rad Laboratories GmbH). The threshold between the positive and negative droplet
clusters was manually set for both fluorochrome channels for each sample. Data
analysis was performed in those samples were 10,000 or more accepted droplets
were obtained.
Lactate dehydrogenase (LDH) release assay and enzyme-linked immunosor-
bent assay (ELISA). Lytic cell death was quantified by determining LDH levels in
the cell-free supernatant using the CytoTox 96 Non-Radioactive Cytotoxicity kit
(Promega G1780), according to the manufacturer’s instructions. Absorbance of
medium was measured to serve as blank value and was subtracted from the sample
values. Results are shown as percentage of 100 % dead cells after lysis with 0.8%
Triton X-100 for 45 min. IL-1β quantification of cell-free supernatants was per-
formed using ELISA, following the manufacturer’s instructions (Invitrogen
88701377). Measurements were performed at least in technical triplicates and
absorbance was detected using a microplate reader.
Reticulocyte counting. Reticulocytes were distinguished from red blood cells by 2
criteria:
1. Size: reticulocytes are larger than erythrocytes: 10–15 mm vs. 6–8 mm
2. Morphology: Reticulocytes have a scattered reticulum network in the
cytoplasm which is visible as a blue granular precipitate.
All experiments were reproducible and were performed at least 3 times.
Statistical analysis. GraphPad Prism v7.01 was used for statistical analysis. A
sample size of at least n= 5 per group was determined by 80% power to reach a
statistical significance of 0.05 to detect an effect size of at least 1.06. For statistical
analysis an unpaired t-test (two-sided) was applied. All data were tested for nor-
mality applying the Kolmogorov–Smirnov test. If the data did not meet the criteria
of normality, the Mann–Whitney U test was applied. Data are presented as mean
and s.e.m. (error bars). Differences were considered significant when the p-value
was <0.05.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data and materials availability
Microarray data are deposited in the database GEO repository under the access ID
GSE131885. The source data underlying Figs. 1C–F, 1H, 2B, C, 2F, 2H, 3B, 3D, 3F, G, 4B,
C, 4F, G, 5A–C, 5F, 5H, I, 6A–F, 6H, 6J, 7C–K, 8A, B, 8D, E, 8G, I, 9B, 9D, 9E–G, 9I–L
and Supplementary Figs. S1A–C, S1G, S2B–C, S4B–E, S5F–I are provided as a Source
Data file.
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